多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗胃癌的疗效比较

目的:比较多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗晚期不可手术胃癌患者的疗效和不良反应。方法:回顾性分析2015年2月至2018年6月126例晚期不可手术的胃癌患者。洛铂组55例:多西他赛+氟尿嘧啶+洛铂，顺铂组71例:多西他赛+氟尿嘧啶+顺铂。洛铂组和顺铂组均21天为一个疗程，连续治疗四个疗程。结果:洛铂组患者客观有效率为50.91%，顺铂组为35.21%，差异无统计学意义（P＞0.05）。洛铂组患者疾病控制率达到83.64%，顺铂组为67.61%，差异有统计学意义（P＜0.05）。洛铂组患者在恶心、呕吐、白细胞减少和四肢麻木方面发生率明显低于顺铂组，差异有统计学意义（P＜0.05）。洛铂组患者血小板减少发生率高于顺铂组，差异有统计学意义（P＜0.05）。洛铂组患者严重不良反应的发生率为21.82%，顺铂组为39.44%，差异具有统计学意义（P＜0.05）。结论:将多西他赛联合氟尿嘧啶、顺铂方案中的顺铂以洛铂替代，取得了更好的疾病控制率，而患者的不良反应更轻，严重不良反应的发生率也更低，值得临床进一步研究。     

乐铂单药治疗42例原发性支气管肺癌

目的：评价德国ＡＳＴＡ药物公司研制的新化疗药物乐铂对小细胞及非小细胞肺癌的治疗效果和不良反应。方法：治疗原发性支气管肺癌４２例，初治２５例，复治１７例；小细胞肺癌３４例，非小细胞肺癌８例。单用乐铂５０ｍｇ／ｍ＾２静脉滴注，共２个周期，２个周期一天。结果：总有效率３０．９％，其中部分缓解（ＰＲ）１３例；小肺癌有效效３８．２％，非小细胞肺癌均儿。该药的剂量限制性毒笥为骨髓抑制，白细胞、血色素下降轻微，     

顺铂与洛铂腹腔灌注治疗胃肠道肿瘤比较分析

 目的: 比较顺铂与洛铂在腹腔灌注化疗中的有效率及副反应。方法:入组患者为我院2007年9月至2009年9月胃癌及大肠癌患者60例,分为2组,一组给以顺铂行腹腔灌注化疗,一组给以洛铂行腹腔灌注化疗,对疗效进行追踪和对比研究。结果：顺铂组30例患者总有效率（ORR）为26.7%;洛铂组30例患者总有效率（ORR）为36.7%;平均无进展生存时间洛铂组与顺铂组存在差异（P＜0.05）; 1年生存率洛铂组与顺铂组存在差异（P＜0.05）; 顺铂组的主要毒性反应表现为神经毒性、骨髓抑制、胃肠道反应。洛铂组的主要毒性反应表现为骨髓抑制、胃肠道反应、血小板下降。结论：洛铂组治疗有效率高于顺铂组。平均无进展生存时间洛铂组高于顺铂组; 1年生存率洛铂组高于顺铂组;不良反应方面：白细胞下降、血红蛋白下降、肝功能损伤及胃肠道反应发生率顺铂组与洛铂组无显著差异。神经毒性、肾功能损伤发生率洛铂组低于顺铂组,血小板下降发生率洛铂组高于顺铂组。     

多西他赛联合洛铂治疗蒽环类耐药的晚期乳腺癌疗效分析

目的:观察多西他赛联合洛铂方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法:采用多西他赛联合洛铂方案治疗晚期乳腺癌患者42例。多西他赛75mg/m2静脉滴注第1天,洛铂30mg/m2静脉滴注第1天。每21天重复,至少应用2个周期。结果:42例患者中,CR、PR分别为4、19例,总有效率为54.8%(23/42),1年生存率为64.3%(27/42),主要不良反应为骨髓抑制。结论:多西他赛联合洛铂方案治疗蒽环类耐药的晚期乳腺癌疗效好,不良反应轻,是治疗蒽环类耐药的晚期乳腺癌较好的方案。     

不同实体瘤体外药敏试验的可行性研究

目的：研究体外药敏试验用于不同原代培养肿瘤细胞的可行性,方法：采用MTT比色分析法,结果：非小细胞肺癌,食管癌,贲门癌对乐铂均较敏感,不同病理类型和同一类型的不同个体对乐铂的敏感性差异较大,且其抑制作 病理类型无密切关系。结论：MTTI地操作简便,快捷,敏感,可应用于实体瘤临床个体化的药敏检测。     

A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

Summary We evaluated the efficacy and tolerability of lobaplatin, a new platinum compound, given at the dose of 50 mg/m² by i.v. bolus every 4 weeks, in 49 patients with advanced and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). One complete and 2 partial responses were observed in 43 eligible patients for an overall response rate of 7% (95% confidence interval: 1–19%). The duration of responses was 11, 16 and 32 weeks. Toxicities of WHO grade 3 were hematologic: thrombocytopenia in 26%, granulocytopenia in 12% and anemia in 12% of patients. There was no therapy-related death. Nausea/vomiting, diarrhoea and paresthesia were mild and rare. In conclusion, lobaplatin was well tolerated, but its efficacy in advanced SCCHN at the presented dose and schedule, was marginal.     

依托泊苷与洛铂联合治疗肺癌导致急性胰腺炎1例报告

正急性胰腺炎(acute pancreatitis,AP)的常见病因有胆道疾病、酗酒、暴饮暴食、外伤等。但有关化学治疗药物引发AP的报道较少见。本文报道1例肺癌化学治疗期间引发AP的病例,以期提高临床医师对此病的关注和重视程度,从而及时发现、正确治疗,并更好地促进用药的合理性与安全性。1病历简介病人女性,62岁。主因"咳嗽伴胸痛40 d"于2015-10-22来哈尔滨医科大学附属第一医院胸外科诊治。病人无     

铜绿假单胞菌注射液胸腔灌注治疗恶性胸腔积液的临床分析

目的观察铜绿假单胞菌注射液胸腔灌注治疗恶性胸腔积液的临床疗效及毒副反应。方法将70例晚期非小细胞肺癌伴恶性胸腔积液患者随机分为观察组和对照组,每组各35例。对照组在常规辅助治疗的基础上予以洛铂胸腔灌注治疗,观察组在对照组的基础上辅以铜绿假单胞菌注射液胸腔灌注,观察比较两组患者治疗后的临床疗效及毒副反应。结果治疗疗程结束后,多数患者胸腔积液情况得到了有效的控制,两组治疗的总有效率分别为77.1%和48.6%(P0.05)。两组患者治疗过程中的毒副反应主要以发热、胃肠道反应及骨髓抑制为主,两组比较差异无统计学意义(P0.05)。结论洛铂联合铜绿假单胞菌注射液比单独洛铂胸腔灌注治疗恶性胸腔积的疗效显著,毒副反应相当,可推荐临床应用。     

Phase II Trial of Loubo® (Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes

Purpose: This phase II study was undertaken to determine the efficacy and safety of Loubo® (Lobaplatin)in combination with pemetrexed in treating patients with metastatic breast cancer who failed to respond toanthracycline or taxanes. Patients and Methods: Metastatic breast cancer cases who had previously received ananthracycline and a taxane in either adjuvant or metastatic settings, were enrolled. All patients were recruitedfrom Jiangsu Cancer Hospital and Research Institute, and were treated with Loubo® (Lobaplatin) 35 mg/m2(intravenous; on day 1) and pemetrexed 500 mg/m2 (intravenous; on day 1) every 21 days. Efficacy and sideeffects were evaluated after at least two cycles of chemotherapy. Results: All eligible 19 patients completed atleast 2 cycles of chemotherapy with pemetrexed and lobaplatin, and were evaluable. Overall, 3 (15.8%) patientsachieved partial response, 11 (57.9%) stable disease, 5 (26.3%) progression of disease, with no complete remission.Response rate was 15.8%, disease control rate was 42.1%. The median survival time was 10.3 months. Neutrophilsuppression occurred in 36.8% of patients who had grade 2 toxicity, and 26.3% had grade 3, 26.4% had grade4. Thrombocytopenia was encountered as follows: 21.1% grade 2, 15.8% grade 3 and 5.5% grade 4. Incidencesof anemia were 10.5% in grade 2, 5.3% grade 3 and 0% grade 4. Only 5.3% of patients required packed redblood cell transfusion. Grade 3 digestive tract toxicity occurred in 5.5% of patients. Other toxicities includedelevated transaminase,oral mucositis and skin rashes. Conclusions: The regimen of lobaplatin and pemetrexed ismodestly active in metastatic breast cancer patients who failed anthracycline or taxanes, and the toxicity profilesuggesting that the doses of chemotherapy should be further modified.     

Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites

Aims: To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patientswith malignant pleural or peritoneal effusions. Methods: Patients in Jiangsu Cancer Hospital and ResearchInstitute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites wereenrolled into this study. Lobaplatin (20-30 mg/m2) was intrapleurally or intraperitoneally infused for patientswith malignant pleural effusion or ascites. Results: From 2012 to 2013, intrapleural or intraperitonea lobaplatinwas administered for patients with colorectal or uterus cancer who were previous treated for malignant pleuraleffusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bonemarrow suppression. No treatment related deaths occurred. Conclusion: Intrapleural or intraperitoneal infusionof lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacyis encouraging.